Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Guillain-Barré syndrome as first presentation of non-Hodgkin lymphoma
Journal Information
Vol. 27. Issue 8.
Pages 511-513 (October 2012)
Vol. 27. Issue 8.
Pages 511-513 (October 2012)
Letter to the Editor
DOI: 10.1016/j.nrleng.2011.10.008
Full text access
Guillain-Barré syndrome as first presentation of non-Hodgkin lymphoma
Síndrome de Guillain-Barré como forma de presentación de un linfoma no Hodgkin
Visits
...
F.J. Polo-Romeroa,??
Corresponding author
fpolo1111@yahoo.es

Corresponding author.
, P. Sánchez-Betetaa, P. Perona-Buendíab, A.M. Pérez-Garcíaa
a Servicio de Medicina Interna, Hospital de Hellín, Albacete, Spain
b Servicio de Medicina Interna, Hospital Los Arcos, San Javier, Murcia, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor:

Guillain-Barré syndrome (GBS) is an autoimmune polyradiculopathy described by Guillain, Barré, and Strohl in 1916 as an acute areflexic motor paralysis with varying degrees of sensory impairment. In Western countries it is the most common cause of acute flaccid tetraparesis.1 In a great many cases, GBS is aetiologically related to a previous infection, which is frequently respiratory or gastrointestinal.2 Researchers have also described GBS cases linked to recent vaccinations,3 haematological malignancies,4 and connective tissue diseases.5 Peripheral nervous system impairment caused by either Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) has been thoroughly described6; however, GBS does not commonly appear as an initial manifestation of NHL.7,8 We present the case of a patient with NHL whose first clinical manifestation was the appearance of GBS.

The patient, a 74-year-old woman with a history of autoimmune hypothyroidism and chronic polyarthralgia with dorsal and lumbar spondylosis, was being treated with levothyroxine and occasional non-steroidal anti-inflammatory drugs. The patient visited our clinic several months ago due to nonspecific asthenia with increased acute-phase reactants (ESR, ferritin, and C-reactive protein). Doctors found no other associated symptoms based on the medical history and examination of organs and organ systems. An exhaustive study including complete blood count, biochemical markers, thyroid function, immunoglobulins, protein electrophoresis, tumour markers, autoimmune study, and antibody serology did not return a diagnosis. A thoracic–abdominal CT scan revealed no changes apart from degenerative signs with no axial skeleton fractures or compressions. She visited the doctor due to symptoms of paraesthesia, weakness in the lower limbs (LL) extending proximally, and lumbar pain that had progressed over 48 h. She was afebrile and had no other associated symptoms. The patient initially presented distal weakness of the lower extremities (grade 3–4/5) with plantar reflex suppression, hypaesthesia of the feet, and no other relevant findings from the neurological examination. Symptoms exacerbated over the next 24 h, and the patient experienced ascending progressive bilateral paralysis that extended to the sites of attachment of both thigh muscles, with tendon reflex suppression in the lower limbs and loss of control over the bladder sphincter. We could not detect a sensory level or any cranial pair involvement. Doctors found no loss of strength or sensitivity in the upper extremities and observed only slight bilateral hyporeflexia of the biceps that could not be confirmed subsequently. In the days that followed, the patient reported paraesthesia in the hands and loss of agility, which could not be detected by the daily physical examination. Cerebellar exam found normal results for the upper extremities, extrinsic eye movements, and photomotor reflex. The patient did not present nystagmus or diplopia. There were no signs of meningeal irritation. The blood test revealed leucocytosis of 22600/μL, ESR 52mm/h, GOT 42U/L, GGT 51U/L, LDH 990U/L, ferritin 551ng/mL and TSH 9.69μU/mL. All other parameters were normal. Thoracic radiography showed no significant findings. Lumbosacral MRI with intravenous contrast did not show significant alterations in the lumbosacral spinal cord or the spinal segments that were viewed (up to D9). A Tc-99m-based bone scan was also performed, revealing uptake at D10, the left sacroiliac joint, shoulders, hips, and knees. These lesions were found to be osteoporotic in origin. A lumbar puncture delivered clear liquid with 20 leucocytes (60% mononuclear and 40% polymorphonuclear), glucose 55mg/dL (plasma glucose 78mg/dL) and proteins 76mg/dL. No oligoclonal bands were observed in the liquid. Both the culture and the anti-Hu antibody titre were negative. The cytological study of the CSF found no malignant cells. A nerve conduction study completed 24 h after the patient's clinical condition had deteriorated showed decreased conduction velocity in the motor nerves examined in the lower limbs. Their morphology and amplitude remained normal. In sensory nerves of the lower limbs, amplitude of action potentials was preserved with a slightly increased duration; nerve conduction speed was slow. Stimulation of the nerves in the lower limbs did not produce any identifiable F-responses. Examination of the median nerve revealed normal sensory and motor parameters and normal F-responses. The study concluded that the patient had a sensory and motor axonal-demyelinating polyneuropathy specifically affecting the lower limbs and compatible with GBS. In view of the diagnosis, the patient was treated with intravenous gammaglobulin (400mg/kg/day during 5 days), but neurological symptoms did not improve. The patient's lack of response to treatment and the fact that there was no clear cause of the neurological symptoms led doctors to believe that she might be suffering from an underlying disease that had not been diagnosed. She later suffered a relapse with the same nonspecific asthenia and increase in acute phase reactants. Doctors detected persistent leucocytosis with no fever and no focal infectious in blood tests. They therefore requested a peripheral blood smear, which revealed pathological alterations. NHL diagnosis was confirmed by bone marrow aspiration and biopsy which showed diffuse infiltration by a B-cell lymphoproliferative process. The haematology department then began administering chemotherapy with CHOP-rituximab. After 6 cycles of treatment (approximately 6 months after diagnosis), the patient's routine bone marrow biopsy showed complete remission. However, a cranial and cervical–thoracic–abdominal–pelvic CT scan showed abnormalities in the cranial vault, left tenth rib, D10 vertebral body, and left iliac blade with soft tissue masses caused by a neoplastic process. At that moment, she had only experienced minimal recovery of strength in the lower limbs (strength grade 1/5). All other neurological alterations remained the same. She was prescribed intrathecal cytarabine and received 6 more cycles of systematic chemotherapy according to the same protocol. A PET-CT scan was performed upon completion of treatment and showed refractory haematological disease, with persistence of lymphomas in the left pleura, both hips, thoracic spine, mediastinum, and retroperitoneal space. In light of these findings, active treatment was cancelled and the patient began receiving palliative care only. She died of septic shock 2 months after chemotherapy was suspended.

Peripheral nervous system impairment caused by lymphoma varies depending on the type of lymphoma and comprises several different kinds of peripheral neuropathies.6,8 This being the case, GBS has been described in association with a number of different haematological neoplasms, but especially with HL.6 However, GBS appearing in association with NHL is very rare and few cases have been described in the literature.7–10 There are only 2 recorded cases in which neurological symptoms appeared prior to the diagnosis of NHL,7,8 as in the case of our patient. The diagnosis of GBS is mainly based on typical clinical data which are then confirmed by results from the CSF analysis and the nerve conduction study.11,12 The clinical data in our case are consistent with a diagnosis of GBS. The most remarkable finding is the appearance of bladder impairment which might be explained by an autonomic dysfunction of that organ.13 Another rarity of this case was the presence of mononuclear pleocytosis in the CSF. This fact should alert doctors to the possibility of an infection or another alternative diagnosis, especially when counts exceed 50cells/μL.5 Nevertheless, this fact has been questioned by other authors14,15 whose research has shown that GBS can appear with pleocytosis, and that once infectious disease has been ruled out, it may even be a typical finding in severe or devastating GBS.15 Studies on the pathogenesis of GBS suggest that antibodies may be directed against different components of the peripheral nervous system.1,2 There is a link between the presence of certain antibodies and the different ways GBS may present and progress. However, the pathogenic significance of these antibodies has not yet been clarified.12 Demyelinating forms of GBS are the most studied by researchers, who have found them to be linked to autoimmune responses to cell membrane gangliosides because of molecular mimicry. However, less than 20% of all cases are positive for anti-ganglioside antibodies.1,16 This inflammatory response mainly occurs in patients who have previously suffered infection with Campylobacter jejuni.1 Many different pathogenic mechanisms are involved in the association between polyneuropathy and lymphoma, but the most accepted ones are direct infiltration of the nerve trunks by lymphoma cells through adjacent ganglia; vascular impairment with nerve infarction; and an immune-mediated inflammatory response of the type occurring in GBS,6 which would therefore constitute a type of paraneoplastic syndrome. On the other hand, peripheral nervous system impairment caused by lymphoma may be due to toxicity caused directly by haematological treatment, especially when high doses of vincristine are used; most published cases of this impairment are caused by vincristine.4,9 GBS is not counted among the classic paraneoplastic neurological syndromes. In this specific case, researchers did not find characteristic onconeural antibodies that would link this neurological syndrome to a concrete type of neoplasia.5 We believe that the most plausible pathophysiological mechanism explaining GBS in this patient would be the development of an immune-mediated paraneoplastic syndrome, since symptoms coincide with the type of GBS typically triggered by a previous infection. We can rule out lymphomatous meningeal infiltration, as in these cases impairment is usually focal or asymmetric.17 We cannot offer a clear explanation for the fact that our patient did not improve after treatment with immunoglobulins or after apparent remission of NHL, but negative outcomes despite conventional treatment are well-documented and the mechanisms explaining treatment failure remain unknown.12 Nevertheless, certain hypotheses may shed light on this subject. First of all, the patient was treated with 12 cycles of chemotherapy (CHOP-rituximab), and it is a known fact that peripheral nervous system impairment can occur with use of any of a number of antineoplastic drugs, including vincristine and rituximab.17,18 These drugs may have contributed to the patient's persistent neurological deterioration. On the other hand, we do not believe that the apparent remission of the lymphoma actually took place, given that staging studies during treatment showed evidence of organ damage. This indicates that the stimulus causing the formation of antibodies was still present19 and explains why neurological symptoms did not abate. There are studies describing cases in which remission of the haematological process caused neurological manifestations to resolve.17 However, in other cases, improvement of the haematological condition was not followed by a good neurological outcome or a favourable response to conventional treatment for GBS.19 To summarise, although the appearance of GBS associated with lymphoma has been described in the literature, it is very rare, especially if it is associated with NHL.7–10 It is rarer still for neurological symptoms to present before the haematological condition has been diagnosed.7,8 We therefore believe it is important to highlight the following: even though it would be quite rare, a case of GBS that cannot be clearly linked to any of the processes or entities with which it is usually associated, which appears with abnormal laboratory results that are not typically seen in classic GBS, or which evolves at an alarming rate and responds poorly to conventional treatment should lead the doctor to consider the possibility of an underlying case of lymphoma.

References
[1]
A. Codina-Puiggrós, C. Cervera-Radigales.
Síndrome de Guillain-Barré.
Med Clin (Barc), 118 (2002), pp. 142-145
[2]
S. Vucic, M.C. Kiernan, D.R. Cornblath.
Guillain-Barré syndrome: an update.
J Clin Neurosci, 16 (2009), pp. 733-741
[3]
M. López-Nieto, J. Gómez-Garrido, A. Losa-Palacios, G. Águila-Manso.
Síndrome de Guillain-Barré secundario a vacunación de gripe A H1 N1.
Rev Clin Esp, 210 (2010), pp. 485-486
[4]
F. Seffo, H.A. Daw.
Non-Hodgkin lymphoma and Guillain-Barré syndrome: a rare association.
Clin Adv Hematol Oncol, 8 (2010), pp. 201-206
[5]
A.H. Ropper.
The Guillain-Barré syndrome.
N Engl J Med, 326 (1992), pp. 1130-1136
[6]
J.J. Kelly, D.S. Karcher.
Lymphoma and peripheral neuropathy: a clinical review.
Muscle Nerve, 31 (2005), pp. 301-313
[7]
C. Gutiérrez-López, N.I. Plascencia-Álvarez, S. Quiñones-Aguilar, A. Venegas-Torres, L. Núñez-Orozco.
Síndrome de Guillain-Barré como manifestación paraneoplásica de linfoma No Hodgkin.
Rev Mex Neuroci, 9 (2008), pp. 239-241
[8]
J.M. Vallat, H.A. De Mascarel, D. Bordessoule, M.O. Jauberteau, F. Tabaraud, A. Gelot, et al.
Non-Hodgkin malignant lymphomas and peripheral neuropathies-13 cases.
Brain, 118 (1995), pp. 1233-1245
[9]
D. Re, A. Schewenk, P. Hegener, S. Bamborschke, V. Diehl, H. Tesch.
Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma.
Ann Oncol, 11 (2000), pp. 217-220
[10]
S. Kivity, B. Shalmon, Y. Sidi.
Guillain-Barre syndrome: an unusual presentation of intravascular lymphoma.
IMAJ, 8 (2006), pp. 137-138
[11]
F.G.A. Van der Meché, P.A. Van Doorn, J. Meulstee, F.G.I. Jennekens, GBS-consensus group of the Dutch Neuromuscular Research Support Centre.
Diagnostic and classification criteria for the Guillain-Barré syndrome.
Eur Neurol, 45 (2001), pp. 133-139
[12]
P.A. Van Doorn, L. Ruts, B.C. Jacobs.
Clinical features, pathogenesis and treatment of Guillain-Barré syndrome.
Lancet Neurol, 7 (2008), pp. 939-950
[13]
D.W. Zochodne.
Autonomic involvement in Guillain-Barré syndrome: a review.
Muscle Nerve, 17 (1994), pp. 1145
[14]
H. Rauschaka, K. Jellinger, H. Lassmann, F. Braier, M. Schmidbauer.
Guillain-Barré syndrome with marked pleocytosis or a significant proportion of polymorphonuclear granulocytes in the cerebrospinal fluid: neuropathological investigation of five cases and review of differential diagnoses.
Eur J Neurol, 10 (2003), pp. 479-486
[15]
J. Berciano, M.T. Berciano, M. Lafarga.
Cerebrospinal fluid pleocytosis with neutrophil leukocytes in Guillain-Barré syndrome.
Eur J Neurol, 11 (2004), pp. 6454-6646
[16]
S. Ramchandren, R.P. Lisak.
The immunopathogenesis of Guillain-Barré syndrome.
Clin Adv Hematol Oncol, 8 (2010), pp. 203-206
[17]
P. Vembu, A. Al-Shubaili, A. Al-Khuraibet, O. Kreze, R. Pandita.
Guillain-Barré síndrome in a case of acute lymphoblastic leukaemia.
Med Clin Pract, 12 (2003), pp. 272-275
[18]
F. Terenghi, G. Ardolino, E. Nobile-Orazio.
Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma.
J Pheripher Nerv Syst, 12 (2007), pp. 142-143
[19]
I. Maslovsky, L. Volchek, R. Blumental, A. Ducach, G. Lugassy.
Persistent paraneoplastic neurologic syndrome after successful therapy of Hodgkin's disease.
Eur J Haematol, 66 (2001), pp. 63-65

Please cite this article as: Polo-Romero FJ, et al. Síndrome de Guillain-Barré como forma de presentación de un linfoma no Hodgkin. Neurología. 2012;27:511–3.

Copyright © 2011. Sociedad Española de Neurología
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.